Tagged with USA

Global Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new CEO leadership team, with appointees from Pfizer, Roche and Daiichi Sankyo.   As the industry’s biggest global trade group that…

USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…

USA David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions. Crean expects to see a continuation of 2023’s strong start to M&A and questions whether the FTC’s newly-aggressive approach will…

Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos highlights the key learnings from this US experience and…

USA Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry veteran Peter Sandor, the company’s SVP and IO Primary Focus Lead. Sandor explains the variety of exciting IO approaches in development at Astellas, how…

USA Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further and sued the US government, arguing that the new legislation violates the constitution, but shareholders at the ICCR are not…

USA Although clinical trial diversity remains high on the agendas of industry sponsors, there is still a long road to travel towards more equitable and representative research – and ultimately safer and more effective medicines. On this theme, writing in the June 2023 edition of the DIA Global Forum magazine, Jorge…

USA Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow Medicare to negotiate prices for the drugs it spends the most on as of 2026. Viehbacher, who was brought in…

USA While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises and equate health security with national security, a necessity that requires consistent public funding. In addition, as a recent panel…

USA During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19 pandemic as well as the backlogs it created and the challenges of carrying the lessons learned forward.   At…

USA During the ongoing BIO International Convention in Boston between June 5th and 8th, the US lobbying group has announced a new board chair in Ted Love as well as a new executive committee.   Love is a longstanding BIO board director and the former President & CEO of Global Blood…

USA Sanskriti Thakur of decentralised clinical trial platform provider Medable, writing in the May 2023 edition of DIA’s Global Forum magazine, argues for an urgent rethink of clinical research to better include a more diverse patient population and protect women, mothers, families, and society at large.   This Mother’s Day, women…